The following article is part of conference coverage from the International Congress of Parkinson’s Disease and Movement Disorders (MDS) Virtual Annual Meeting. Neurology Advisor’s staff will be reporting breaking news associated with research conducted by leading experts in neurology. Check back for the latest news from the MDS 2021 Virtual Annual Meeting.
Ecopipam, a selective D1 antagonist, has shown long-term safety and activity in children with Tourette syndrome, according to study results presented at the International Congress of Parkinson’s Disease and Movement Disorders (MDS) Virtual Congress 2021, held from September 17 to 22, 2021.
Although earlier studies have supported the efficacy of treatment with D2 antagonists for Tourette syndrome in children, potential risk for weight gain and extrapyramidal symptoms should be considered.
The objective of the current study was to determine the long-term safety and activity of ecopipam in children and adolescents with Tourette syndrome.
The open-label, single-arm extension study included children aged older than 7 years and younger 18 years, with both motor and vocal tics and a Yale Global Tic Severity Scale (YGTSS-TTS) of 20 or more, who had previously completed a double-blind phase 2 crossover proof-of-concept study.
The change from baseline to 12 months on the YGTSS-TTS was the primary endpoint. The change from baseline to 12 months on the Clinical Global Impression (CGI)-Improvement and CGI-Severity scale were the key secondary endpoints. Safety analysis included data on laboratory findings, adverse events, and the Children’s Depression Inventory.
The study sample included 26 patients (mean age, 13.4 years), with a mean exposure of 366 days.
At 12 months, treatment with ecopipam was associated with a significant improvement on the YGYSS-TTS (mean change, -11.8; 95% CI, -17.1 to -6.5; P =.0003). Significant improvements on the YGYSS-TSS were also noted at 3, 6, and 9 months. Significant improvements at 12 months were also recorded on the CGI-Improvement (P <.0001) and CGI-Severity (P =.001) scales.
Regarding safety, suicidal ideation was the most common adverse event (n=3), followed by decreased appetite, depressed mood, and irritability (n=2each). There were no extrapyramidal or metabolic adverse events. Although most adverse events, were mild and moderate, they were the reason for treatment discontinuation among 4 patients (15.4%). One patient had a serious adverse event of anxiety.
“Ecopipam demonstrated sustained, -year reduction in motor and phonic tics in pediatric [Tourette syndrome] patients, with no extra-pyramidal side effects or weight gain,” the researchers concluded.
Gilbert DL, Chipkin R, Mahableshwarkar A. Long-term safety and activity of ecopipam (ECO), a selective D1 antagonist during treatment of pediatric patients with Tourette Syndrome. Presented at: MDS Virtual Congress 2021; September 17-22, 2021. Abstract 68.